RADIATION THERAPY ONCOLOGY GROUP

放射治疗肿瘤学组

基本信息

项目摘要

The support requested in this application is for the ongoing participation of the Department of Radiation Oncology of the University of California, San Francisco, and its affiliate institutions (the University of California, San Diego; the University of California, Irvine; and Fresno Community Hosptial of the UCSF Fresno campus) in the activities of the Radiation Therapy Oncology Group (RTOG). The Department of Radiation Oncology at UCSF is comprised of facilities at four institutions, that of Moffitt - Long Hospital, Mt. Zion Hospital, Franklin Hospital, and the Lawrence Berkeley Laboratory, together treating 2,700 new patients per year. UCSF has participated in the RTOG since 1972 and are entering approximately 150 patients per year into various group Phase I/II/III protocols. Faculty members of the Department of Radiation Oncology at UCSF have served under various committees and provided scientific input into many of the RTOG protocols especially in the areas of radiosensitizers, radioprotectors, isotopic immunotherapy, head and neck, CNS, and GYN tumors and brain and liver metastases. Dr. Theodore L. Philips, the Associate Principal Investigator and the Vice-chairman of the RTOG Modality Committee was instrumental in the introduction of the radiosensitizer Misonidazole into clinical use in the United States. The Department of Radiation Oncology at UCSF was the primary institution wherein a number of Phase I/II radiosensitizers protocols were carried out. Support through this application will allow continued RTOG participation by the Department of Radiation Oncology at UCSF and its affiliate institutions with the goal of accessing 150-175 patients per year into various RTOG Protocols. Extensive research into hyperthermia, chemical modification of radiation effects, and radioimmunotherapy is expected to lead to innovative protocol development within the group with a corresponding increase in the accession of patients into studies sponsored by the RTOG.
此申请中要求的支持是针对正在进行的参与

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Evaluation of the bioavailability of misonidazole (NSC#261037) in capsule and tablet form and pharmacologic effects of daily dosage.
米索硝唑的生物利用度评价(NSC
Promise of radiosensitizers and radioprotectors in the treatment of human cancer.
放射增敏剂和放射防护剂在治疗人类癌症中的前景。
  • DOI:
  • 发表时间:
    1984
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Phillips,TL;Wasserman,TH
  • 通讯作者:
    Wasserman,TH
Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
缺氧细胞放射增敏剂米索硝唑美国 I 期临床试验最终报告(Ro-07-0582;NSC)
  • DOI:
    10.1002/1097-0142(19811015)48:8<1697::aid-cncr2820480802>3.0.co;2-w
  • 发表时间:
    1981
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Phillips,TL;Wasserman,TH;Johnson,RJ;Levin,VA;VanRaalte,G
  • 通讯作者:
    VanRaalte,G
Clinical trials of hypoxic cell sensitizers.
缺氧细胞敏化剂的临床试验。
Palliation of liver metastases with combined hepatic irradiation and misonidazole. Results of a Radiation Therapy Oncology Group Phase I-II study.
联合肝照射和米索硝唑缓解肝转移。
  • DOI:
  • 发表时间:
    1981
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Leibel,SA;Order,SE;Rominger,CJ;Asbell,SO
  • 通讯作者:
    Asbell,SO
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Theodore Phillips其他文献

Theodore Phillips的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Theodore Phillips', 18)}}的其他基金

HEAVY ION STUDIES
重离子研究
  • 批准号:
    6101883
  • 财政年份:
    1996
  • 资助金额:
    $ 3.61万
  • 项目类别:
3D DOSE ESCALATION FOR PROSTATE CANCER
前列腺癌的 3D 剂量递增
  • 批准号:
    2100975
  • 财政年份:
    1993
  • 资助金额:
    $ 3.61万
  • 项目类别:
3D DOSE ESCALATION FOR PROSTATE CANCER
前列腺癌的 3D 剂量递增
  • 批准号:
    3550103
  • 财政年份:
    1993
  • 资助金额:
    $ 3.61万
  • 项目类别:
3D DOSE ESCALATION FOR PROSTATE CANCER
前列腺癌的 3D 剂量递增
  • 批准号:
    2100974
  • 财政年份:
    1993
  • 资助金额:
    $ 3.61万
  • 项目类别:
3D DOSE ESCALATION FOR PROSTATE CANCER
前列腺癌的 3D 剂量递增
  • 批准号:
    2100976
  • 财政年份:
    1993
  • 资助金额:
    $ 3.61万
  • 项目类别:
RESEARCH BASE FOR SAN JOAQUIN VALLEY COMMUNITY CLINICAL
圣华金谷社区临床研究基地
  • 批准号:
    3558157
  • 财政年份:
    1983
  • 资助金额:
    $ 3.61万
  • 项目类别:
RESEARCH BASE FOR SAN JOAQUIN VALLEY COMMUNITY CLINICAL
圣华金谷社区临床研究基地
  • 批准号:
    3558158
  • 财政年份:
    1983
  • 资助金额:
    $ 3.61万
  • 项目类别:
NORTHERN CALIFORNIA CANCER PROGRAM CCOP RESEARCH BASE
北加州癌症计划 CCOP 研究基地
  • 批准号:
    3558156
  • 财政年份:
    1983
  • 资助金额:
    $ 3.61万
  • 项目类别:
NORTHERN CALIFORNIA CANCER PROGRAM CCOP RESEARCH BASE
北加州癌症计划 CCOP 研究基地
  • 批准号:
    3558159
  • 财政年份:
    1983
  • 资助金额:
    $ 3.61万
  • 项目类别:
RADIATION THERAPY ONCOLOGY GROUP
放射治疗肿瘤学组
  • 批准号:
    3556603
  • 财政年份:
    1979
  • 资助金额:
    $ 3.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了